Dapagliflozin for the treatment of type 2 diabetes

Bibliography

• Danaei G, Finucane MM, Lu Y, et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011;378:31-40
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30
   PubMed Web of Science ®Google Scholar
• The American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007;30(Supp I):S4-S41
   Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94
   PubMed Web of Science ®Google Scholar
• Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-9
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 1971;28:183-93
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Med Chem 2008;251:1145-9
   Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharm Ther 2009;85:513
   PubMed Web of Science ®Google Scholar
• Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-204
   PubMed Web of Science ®Google Scholar
• Abdul-ghani MA, DeFronzo RA, Norton L. A novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans? Diabetes 2013; In press
   Google Scholar
• DeFronzo RA, Hompesch M, Kasichayanula S, et al. Dapagliflozin reduces renal threshold for glucose excretion in type 2 diabetes. Diabetologia 2012;55(Suppl):A747
   Google Scholar
• Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2011;13:770-3
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47-54
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Tang W, et al. Dapagliflozin monotherapy in T2DM patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, multicenter phase III trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Iqbal N, T'joen C, et al. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951-9
   PubMed Web of Science ®Google Scholar
• Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012; Epub ahead of print
   Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Baily CJ, Gross JI, Yadav M, et al. Sustained efficacy of dapagliflozin when added to metformin in type 2 diabetes inadequately controlled by metformin monotherapy. Diabetologia 2011;54(Suppl 1):A146
   PubMedGoogle Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
   PubMed Web of Science ®Google Scholar
• Del Prato S, Nauck M, Rohwedder K, et al. Long term efficacy and safety of ass-on dapagliflozin vs add-on glipizide in patients with type 2 diabetes mellitus inadequately controlled with metformin: 2 year results. Diabetologia 2011;54(Suppl1):A852
   PubMedGoogle Scholar
• Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Norwood P, Tjoen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Inter Med 2012;156:405-15
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diab Obesity Metab 2010;12:510-16
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Benito MP, et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment. J Am Soc Nephrol 2011;22:232A-3A
   Google Scholar
• Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
   PubMed Web of Science ®Google Scholar
• Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999;10:2569-76
   PubMed Web of Science ®Google Scholar
• Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol 2004;286:F8-F18
   PubMed Web of Science ®Google Scholar
• Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012;302:R75-83
   PubMed Web of Science ®Google Scholar
• Noonan WT, Shapiro VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci 2001;68:2967-77
   PubMedGoogle Scholar
• Dominguez JH, Camp K, Maianu L, et al. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 1994;266:F283-90
   PubMed Web of Science ®Google Scholar
• Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996;335:1636-42
   PubMedGoogle Scholar
• Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991;324:1626-32
   PubMed Web of Science ®Google Scholar
• Parikh S, Johnsson K, Ptaszynska A, et al. Characterization of urinary tract infection in the setting of pharmacologically induced glucosuria. Diabetologia 2011;54(Suppl):A841
   Google Scholar
• Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar